CytoDyn Inc. Announces Encouraging Clinical Trial Findings in Metastatic Colorectal Cancer with Leronlimab at ESMO Congress 2025

Reuters07-01

<a href="https://laohu8.com/S/CYDY">CytoDyn Inc.</a> Announces Encouraging Clinical Trial Findings in Metastatic Colorectal Cancer with Leronlimab at ESMO Congress 2025

CytoDyn Inc. announced positive clinical findings from their ongoing Phase II trial involving leronlimab in patients with advanced metastatic colorectal cancer (mCRC). The results, obtained from patients treated under a compassionate use protocol, demonstrate a favorable safety profile and potential clinical benefits. Notably, 3 out of 5 patients exhibited at least a partial response, with one achieving a complete response and remaining alive five years later. The final results of this study will be presented by Dr. Benjamin Weinberg, Associate Professor at Georgetown University and Principal Investigator of CytoDyn's colorectal cancer program, at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona, Spain. The company is actively enrolling additional patients to confirm these observations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9487214-en) on July 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2548094090?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-01 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548094090","market":"fut","top_or_hot":-1,"title":"CytoDyn Inc. Announces Encouraging Clinical Trial Findings in Metastatic Colorectal Cancer with Leronlimab at ESMO Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CYDY\">CytoDyn Inc.</a> Announces Encouraging Clinical Trial Findings in Metastatic Colorectal Cancer with Leronlimab at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CytoDyn Inc. announced positive clinical findings from their ongoing Phase II trial involving leronlimab in patients with advanced metastatic colorectal cancer (mCRC). The results, obtained from patients treated under a compassionate use protocol, demonstrate a favorable safety profile and potential clinical benefits. Notably, 3 out of 5 patients exhibited at least a partial response, with one achieving a complete response and remaining alive five years later. The final results of this study will be presented by Dr. Benjamin Weinberg, Associate Professor at Georgetown University and Principal Investigator of CytoDyn's colorectal cancer program, at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona, Spain. The company is actively enrolling additional patients to confirm these observations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9487214-en) on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CytoDyn Inc. Announces Encouraging Clinical Trial Findings in Metastatic Colorectal Cancer with Leronlimab at ESMO Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytoDyn Inc. Announces Encouraging Clinical Trial Findings in Metastatic Colorectal Cancer with Leronlimab at ESMO Congress 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-01 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CYDY\">CytoDyn Inc.</a> Announces Encouraging Clinical Trial Findings in Metastatic Colorectal Cancer with Leronlimab at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CytoDyn Inc. announced positive clinical findings from their ongoing Phase II trial involving leronlimab in patients with advanced metastatic colorectal cancer (mCRC). The results, obtained from patients treated under a compassionate use protocol, demonstrate a favorable safety profile and potential clinical benefits. Notably, 3 out of 5 patients exhibited at least a partial response, with one achieving a complete response and remaining alive five years later. The final results of this study will be presented by Dr. Benjamin Weinberg, Associate Professor at Georgetown University and Principal Investigator of CytoDyn's colorectal cancer program, at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona, Spain. The company is actively enrolling additional patients to confirm these observations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9487214-en) on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL78LLbp:1","article_id":"2548094090","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548094090","pubTimestamp":1751373041,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CytoDyn Inc. Announces Encouraging Clinical Trial Findings in Metastatic Colorectal Cancer with Leronlimab at ESMO Congress 2025. CytoDyn Inc. announced positive clinical findings from their ongoing Phase II trial involving leronlimab in patients with advanced metastatic colorectal cancer . The results, obtained from patients treated under a compassionate use protocol, demonstrate a favorable safety profile and potential clinical benefits. Notably, 3 out of 5 patients exhibited at least a partial response, with one achieving a complete response and remaining alive five years later. The final results of this study will be presented by Dr. Benjamin Weinberg, Associate Professor at Georgetown University and Principal Investigator of CytoDyn's colorectal cancer program, at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona, Spain. The company is actively enrolling additional patients to confirm these observations.Disclaimer: This news brief was created by Public Technologies  usi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","CYDY":"CytoDyn Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"CytoDyn Inc.在2025年ESMO大会上宣布Leronlimab治疗转移性结直肠癌的令人鼓舞的临床试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYDY":0.9,"NDAQ":0.9},"content_text":"CytoDyn Inc. Announces Encouraging Clinical Trial Findings in Metastatic Colorectal Cancer with Leronlimab at ESMO Congress 2025\n    \n\n        CytoDyn Inc. announced positive clinical findings from their ongoing Phase II trial involving leronlimab in patients with advanced metastatic colorectal cancer (mCRC). The results, obtained from patients treated under a compassionate use protocol, demonstrate a favorable safety profile and potential clinical benefits. Notably, 3 out of 5 patients exhibited at least a partial response, with one achieving a complete response and remaining alive five years later. The final results of this study will be presented by Dr. Benjamin Weinberg, Associate Professor at Georgetown University and Principal Investigator of CytoDyn's colorectal cancer program, at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona, Spain. The company is actively enrolling additional patients to confirm these observations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9487214-en) on July 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548094090","isCrawlerRequest":true}